Gentian Diagnostics ASA (GENT.OL)

NOK 39.0

(0.0%)

EBITDA Summary of Gentian Diagnostics ASA

Gentian Diagnostics ASA's latest annual EBITDA in 2023 was -3.92 Million NOK , up 67.65% from previous year.
Gentian Diagnostics ASA's latest quarterly EBITDA in 2024 Q2 was 5.82 Million NOK , up 0.37% from previous quarter.
Gentian Diagnostics ASA reported an annual EBITDA of -15.93 Million NOK in 2022, up 30.52% from previous year.
Gentian Diagnostics ASA reported an annual EBITDA of -18.38 Million NOK in 2021, down -55.82% from previous year.
Gentian Diagnostics ASA reported a quarterly EBITDA of 6.4 Million NOK for 2024 Q3, down -5.67% from previous quarter.
Gentian Diagnostics ASA reported a quarterly EBITDA of 6.76 Million NOK for 2024 Q1, up 206.17% from previous quarter.

Annual EBITDA Chart of Gentian Diagnostics ASA (2023 - 2013)

Historical Annual EBITDA of Gentian Diagnostics ASA (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	-3.92 Million NOK	67.65%
2022	-15.93 Million NOK	30.52%
2021	-18.38 Million NOK	-55.82%
2020	-12.52 Million NOK	41.74%
2019	-21.02 Million NOK	-186.43%
2018	-15.77 Million NOK	44.6%
2017	-12.1 Million NOK	-82.84%
2016	-6.62 Million NOK	-323.25%
2015	-1.56 Million NOK	-20.46%
2014	-1.29 Million NOK	-162.34%
2013	1.46 Million NOK	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	5.82 Million NOK	0.37%
2024 Q3	6.4 Million NOK	-5.67%
2024 Q1	6.76 Million NOK	206.17%
2023 Q4	-1.32 Million NOK	-155.05%
2023 FY	- NOK	67.65%
2023 Q1	2 Million NOK	137.22%
2023 Q3	2.39 Million NOK	-47.73%
2023 Q2	4.58 Million NOK	129.4%
2022 Q3	-5.22 Million NOK	-427.85%
2022 Q1	-3.11 Million NOK	72.44%
2022 FY	- NOK	30.52%
2022 Q4	-5.37 Million NOK	-2.83%
2022 Q2	1.59 Million NOK	151.2%
2021 Q3	-3.5 Million NOK	-338.5%
2021 FY	- NOK	-55.82%
2021 Q2	-800 Thousand NOK	58.85%
2021 Q1	-1.94 Million NOK	-77.86%
2021 Q4	-11.29 Million NOK	-221.98%
2020 Q2	238 Thousand NOK	104.87%
2020 Q1	-4.88 Million NOK	73.46%
2020 FY	- NOK	41.74%
2020 Q4	-1.09 Million NOK	79.95%
2020 Q3	-5.45 Million NOK	-2390.76%
2019 FY	- NOK	-186.43%
2019 Q4	-18.42 Million NOK	-312.73%
2019 Q3	-4.46 Million NOK	-147.92%
2019 Q1	-5.64 Million NOK	24.13%
2019 Q2	9.31 Million NOK	265.04%
2018 Q4	-7.43 Million NOK	-3763.81%
2018 FY	- NOK	44.6%
2018 Q1	-3.05 Million NOK	-27.27%
2018 Q2	-1.45 Million NOK	52.27%
2018 Q3	203 Thousand NOK	113.92%
2017 Q4	-2.4 Million NOK	44.62%
2017 Q2	857 Thousand NOK	118.07%
2017 Q1	-4.74 Million NOK	-207.51%
2017 FY	- NOK	-82.84%
2017 Q3	-4.33 Million NOK	-605.72%
2016 Q4	-1.54 Million NOK	63.57%
2016 Q2	30 Thousand NOK	104.69%
2016 Q1	-640 Thousand NOK	63.32%
2016 FY	- NOK	-323.25%
2016 Q3	-4.23 Million NOK	-14210.0%
2015 FY	- NOK	-20.46%
2015 Q3	-563 Thousand NOK	0.0%
2015 Q4	-1.74 Million NOK	-209.91%
2014 FY	- NOK	-162.34%
2013 FY	- NOK	0.0%

Peer EBITDA Comparison of Gentian Diagnostics ASA

Name	EBITDA	EBITDA Difference
Lifecare AS	-32.09 Million NOK	87.783%
Medistim ASA	155.09 Million NOK	102.528%